Gastroenterology
Volume 129, Issue 3 , Pages 874-884 , September 2005

Gene-Expression Profiling Predicts Recurrence in Dukes’ C Colorectal Cancer

  • Diego Arango

      Affiliations

    • Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
    • Molecular Biology and Biochemistry Research Center (CIBBIM), Valle Hebron Research Institute, Barcelona, Spain
    • Corresponding Author InformationAddress requests for reprints to: Diego Arango, PhD, Molecular Biology and Biochemistry Research Center (CIBBIM), Valle Hebron University Hospital, Passeig Vall d’Hebron 119-129, Barcelona 08035, Spain. fax: (34) 93-489-4040.
    • ,
  • Paivi Laiho

      Affiliations

    • Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
    • ,
  • Antti Kokko

      Affiliations

    • Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
    • ,
  • Pia Alhopuro

      Affiliations

    • Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
    • ,
  • Heli Sammalkorpi

      Affiliations

    • Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
    • ,
  • Reijo Salovaara

      Affiliations

    • Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
    • Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland
    • ,
  • Daniel Nicorici

      Affiliations

    • Institute of Signal Processing, Tampere University of Technology, Tampere, Finland
    • ,
  • Sampsa Hautaniemi

      Affiliations

    • Institute of Signal Processing, Tampere University of Technology, Tampere, Finland
    • ,
  • Hafid Alazzouzi

      Affiliations

    • Molecular Biology and Biochemistry Research Center (CIBBIM), Valle Hebron Research Institute, Barcelona, Spain
    • ,
  • Jukka–Pekka Mecklin

      Affiliations

    • Department of Surgery, Jyväskylä Central Hospital, Jyväskylä, Finland
    • ,
  • Heikki Järvinen

      Affiliations

    • Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland
    • ,
  • Akseli Hemminki

      Affiliations

    • Cancer Gene Therapy Group, University of Helsinki, and Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • Jaakko Astola

      Affiliations

    • Institute of Signal Processing, Tampere University of Technology, Tampere, Finland
    • ,
  • Simo Schwartz Jr

      Affiliations

    • Molecular Biology and Biochemistry Research Center (CIBBIM), Valle Hebron Research Institute, Barcelona, Spain
    • ,
  • Lauri A. Aaltonen

      Affiliations

    • Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland

Received 10 November 2004 ,Accepted 9 June 2005.

References 

  1. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma . N Engl J Med . 1990;322:352–358
  2. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al  Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma (a final report) . Ann Intern Med . 1995;122:321–326
  3. Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair GE, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer . Gastroenterology . 1993;104:57–64
  4. Benhattar J , Losi L , Chaubert P , Givel JC , Costa J . Prognostic significance of K-ras mutations in colorectal carcinoma . Gastroenterology . 1993;104:1044–1048
  5. Goh HS , Yao J , Smith DR . p53 point mutation and survival in colorectal cancer patients . Cancer Res . 1995;55:5217–5221
  6. Ogunbiyi OA, Goodfellow PJ, Herfarth K, Gagliardi G, Swanson PE, Birnbaum EH, et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator . J Clin Oncol . 1998;16:427–433
  7. Lanza G, Matteuzzi M, Gafa R, Orvieto E, Maestri I, Santini A, et al. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer . Int J Cancer . 1998;79:390–395
  8. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer . N Engl J Med . 2001;344:1196–1206
  9. Laurent-Puig P, Olschwang S, Delattre O, Remvikos Y, Asselain B, Melot T, et al  Survival and acquired genetic alterations in colorectal cancer . Gastroenterology . 1992;102:1136–1141
  10. Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer . N Engl J Med . 1994;331:213–221
  11. Diep CB , Thorstensen L , Meling GI , Skovlund E , Rognum TO , Lothe RA . Genetic tumor markers with prognostic impact in Dukes’ stages B and C colorectal cancer patients . J Clin Oncol . 2003;21:820–829
  12. Cohn KH, Ornstein DL, Wang F, LaPaix FD, Phipps K, Edelsberg C, et al. The significance of allelic deletions and aneuploidy in colorectal carcinoma. Results of a 5-year follow-up study . Cancer . 1997;79:233–244
  13. Schena M , Shalon D , Davis RW , Brown PO . Quantitative monitoring of gene expression patterns with a complementary DNA microarray . Science . 1995;270:467–470
  14. Augenlicht LH , Kobrin D . Cloning and screening of sequences expressed in a mouse colon tumor . Cancer Res . 1982;42:1088–1093
  15. Wodicka L , Dong H , Mittmann M , Ho MH , Lockhart DJ . Genome-wide expression monitoring in Saccharomyces cerevisiae . Nat Biotechnol . 1997;15:1359–1367
  16. Mahadevappa M , Warrington JA . A high-density probe array sample preparation method using 10- to 100-fold fewer cells . Nat Biotechnol . 1999;17:1134–1136
  17. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification of cancer (class discovery and class prediction by gene expression monitoring) . Science . 1999;286:531–537
  18. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling . Nature . 2000;403:503–511
  19. Kihara C, Tsunoda T, Tanaka T, Yamana H, Furukawa Y, Ono K, et al. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles . Cancer Res . 2001;61:6474–6479
  20. Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes’ B colon cancer . J Clin Oncol . 2004;22:1564–1571
  21. Tusher VG , Tibshirani R , Chu G . Significance analysis of microarrays applied to the ionizing radiation response . Proc Natl Acad Sci U S A . 2001;98:5116–5121
  22. Zeeberg BR, Feng W, Wang G, Wang MD, Fojo AT, Sunshine M, et al. GoMiner (a resource for biological interpretation of genomic and proteomic data) . Genome Biol . 2003;4:R28
  23. Eisen MB , Spellman PT , Brown PO , Botstein D . Cluster analysis and display of genome-wide expression patterns . Proc Natl Acad Sci U S A . 1998;95:14863–14868
  24. Lloyd SP . Least square quantization in PCM . Trans Information Theory . 1982;IT-28:129–137
  25. Arango D, Wilson AJ, Shi Q, Corner GA, Arañes MJ, Nicholas C, et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells . Br J Cancer . 2004;91:1931–1946
  26. Mariadason JM, Arango D, Shi Q, Wilson AJ, Corner GA, Nicholas C, et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin . Cancer Res . 2003;63:8791–8812
  27. Arango D, Mariadason JM, Willson AJ, Yang W, Corner GA, Arañes MJ, et al. c-Myc overexpression sensitizes colon cancer cells to camptothecin-induced apoptosis . Br J Cancer . 2003;89:1757–1765
  28. Alhopuro P, Alazzouzi H, Sammalkorpi H, Salovaara R, Hemminki A, Järvinen H, Mecklin JP, Aaltonen LA, Arango D. SMAD4 levels and response to 5-fluorouracil in colorectal cancer. Clin Cancer Res (in press).
  29. Servomaa K , Kiuru A , Kosma VM , Hirvikoski P , Rytomaa T . p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women . Mol Pathol . 2000;53:24–30
  30. Laiho P, Launonen V, Lahermo P, Esteller M, Guo M, Herman JG, et al. Low-level microsatellite instability in most colorectal carcinomas . Cancer Res . 2002;62:1166–1170
  31. Hsu IC , Metcalf RA , Sun T , Welsh JA , Wang NJ , Harris CC . Mutational hotspot in the p53 gene in human hepatocellular carcinomas . Nature . 1991;350:427–428
  32. Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Järvinen H, Mecklin JP, et al. SMAD4 as a prognostic marker in colorectal cancer . Clin Cancer Res . 2005;11:2606–2611
  33. Canzian F, Salovaara R, Hemminki A, Kristo P, Chadwick R, Aaltonen L, et al. Semiautomated assessment of loss of heterozygosity and replication error in tumors . Cancer Res . 1996;56:3331–3337
  34. Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T, et al. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma . Lab Invest . 2003;83:861–870
  35. Mariadason JM, Arango D, Corner GA, Aranes MJ, Hotchkiss KA, Yang W, et al. A gene expression profile that defines colon cell maturation in vitro . Cancer Res . 2002;62:4791–4804
  36. Rihet S , Vielh P , Camonis J , Goud B , Chevillard S , de Gunzburg J . Mutation status of genes encoding RhoA, Rac1, and Cdc42 GTPases in a panel of invasive human colorectal and breast tumors . J Cancer Res Clin Oncol . 2001;127:733–738
  37. Moscow JA, He R, Gnarra JR, Knutsen T, Weng Y, Zhao WP, et al. Examination of human tumors for rhoA mutations . Oncogene . 1994;9:189–194
  38. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, et al. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers . Nat Med . 2004;10:1251–1256
  39. Fukata M , Kaibuchi K . Rho-family GTPases in cadherin-mediated cell-cell adhesion . Nat Rev Mol Cell Biol . 2001;2:887–897
  40. Kau TR , Way JC , Silver PA . Nuclear transport and cancer (from mechanism to intervention) . Nat Rev Cancer . 2004;4:106–117
  41. Garrido C , Gurbuxani S , Ravagnan L , Kroemer G . Heat shock proteins (endogenous modulators of apoptotic cell death) . Biochem Biophys Res Commun . 2001;286:433–442
  42. Rao RV , Ellerby HM , Bredesen DE . Coupling endoplasmic reticulum stress to the cell death program . Cell Death Differ . 2004;11:372–380
  43. Brunagel G , Shah U , Schoen RE , Getzenberg RH . Identification of calreticulin as a nuclear matrix protein associated with human colon cancer . J Cell Biochem . 2003;89:238–243
  44. Schubert A , Grimm S . Cyclophilin D, a component of the permeability transition-pore, is an apoptosis repressor . Cancer Res . 2004;64:85–93
  45. Xanthoudakis S, Roy S, Rasper D, Hennessey T, Aubin Y, Cassady R, et al. Hsp60 accelerates the maturation of pro-caspase-3 by upstream activator proteases during apoptosis . EMBO J . 1999;18:2049–2056
  46. Han JM , Kim JY , Kim S . Molecular network and functional implications of macromolecular tRNA synthetase complex . Biochem Biophys Res Commun . 2003;303:985–993
  47. Francklyn C , Perona JJ , Puetz J , Hou YM . Aminoacyl-tRNA synthetases (versatile players in the changing theater of translation) . RNA . 2002;8:1363–1372
  48. Bos JL . ras oncogenes in human cancer (a review) . Cancer Res . 1989;49:4682–4689
  49. Oliveira C, Westra JL, Arango D, Ollikainen M, Domingo E, Ferreira A, et al. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status . Hum Mol Genet . 2004;13:2303–2311
  50. Jaffe AB , Hall A . Rho GTPases in transformation and metastasis . Adv Cancer Res . 2002;84:57–80
  51. Vial E , Sahai E , Marshall CJ . ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility . Cancer Cell . 2003;4:67–79
  52. Cox EA , Sastry SK , Huttenlocher A . Integrin-mediated adhesion regulates cell polarity and membrane protrusion through the Rho family of GTPases . Mol Biol Cell . 2001;12:265–277
  53. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer . J Clin Oncol . 2000;18:2938–2947
  54. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer . J Clin Oncol . 2000;18:136–147
  55. Cunningham D, Pyrhonen S, James RD, Punt CJA, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer . Lancet . 1998;352:1413–1418
  56. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer (a multicentre randomised trial) . Lancet . 2000;355:1041–1047
  57. Arango D , Augenlicht LH . In: New approaches to colorectal cancer treatment. Recent research developments in cancer . Volume 3: Trivandrum, India: Transworld Research Network; 2001;p. 385–395

 Supported by grants from the Sigrid Juselius Foundation (to D.A.; 2003 and 2004) and grants from the Academy of Finland (to L.A.A.; grant 44870, Finnish Center of Excellence Program 2000 to 2005). H.A. is supported by a fellowship from the Agéncia de Gestió d’Ajuts Universitaris i de Recerca de la Generalitat de Catalunya.

PII: S0016-5085(05)01354-5

doi: 10.1053/j.gastro.2005.06.066

Gastroenterology
Volume 129, Issue 3 , Pages 874-884 , September 2005

Article Tools

* Image Usage & Resolution